PDCD1 and neoplasm: Tislelizumab, a monoclonal immunoglobulin G4 antibody, has been designed to effectively disrupt programmed cell death-1 (PD-1)/PD-L1 binding and minimize binding to Fcγ receptors.16 Given its promising anti-tumor effects, tislelizumab has been approved in China for use in several solid tumors.16 The clinical benefit observed with neoadjuvant tislelizumab plus chemotherapy had been confirmed in the TD-NICE phase II study for resectable esophageal cancer, showing encouraging antitumor activity (pathological complete response [pCR] of 50%) and acceptable tolerability.17